Goserelin belongs to the GnRH agonist class of peptides. Unlike the endogenous GnRH pulse, which stimulates gonadotropin release in a rhythmic pattern, continuous administration of goserelin causes receptor downregulation and desensitisation at the pituitary level. The net effect , after an initial brief "flare" of LH and FSH , is sustained suppression of testosterone (in males) and oestradiol (in females) to castrate or post-menopausal levels. This pharmacodynamic profile is distinct from GnRH antagonists, which block the receptor directly without the initial flare phase.
Structurally, goserelin is a ten-amino-acid peptide with a synthetic D-Ser(tBu) substitution at position 6 and an azgly-NH₂ modification at position 10, both of which confer resistance to enzymatic degradation and extend the molecule's biological half-life relative to native GnRH. It is formulated as a biodegradable subcutaneous depot implant, releasing drug at a controlled rate over one or three months , a delivery approach that reflects the practical challenge of peptide oral bioavailability.
In Australia, goserelin is a Schedule 4 (Prescription Only Medicine) under the Therapeutic Goods Administration (TGA) Poisons Standard. It is listed on the Australian Register of Therapeutic Goods (ARTG) and may only be lawfully supplied by or on the prescription of an authorised medical practitioner. Goserelin has no approved indication for performance enhancement, body composition, or anti-ageing purposes; any supply of a peptide product outside TGA approval pathways is illegal under the Therapeutic Goods Act 1989 (Cth).
Research into goserelin's pharmacology has been conducted across a range of approved clinical contexts, with the molecule examined in published peer-reviewed literature as a tool for studying hypothalamic–pituitary–gonadal (HPG) axis physiology. Like all prescription-only peptides, its use is subject to ongoing TGA regulatory oversight, and healthcare professionals accessing it must comply with prescribing obligations under state and territory medicines legislation.
Sources: